Provided by Tiger Trade Technology Pte. Ltd.

3SBIO

16.570
+0.6504.08%
Volume:31.19M
Turnover:508.11M
Market Cap:41.74B
PE:4.13
High:16.610
Open:15.870
Low:15.700
Close:15.920
52wk High:34.905
52wk Low:14.594
Shares:2.52B
HK Float Shares:2.52B
Volume Ratio:1.73
T/O Rate:1.24%
Dividend:0.25
Dividend Rate:1.51%
EPS(LYR):4.008
ROE:35.88%
ROA:22.68%
PB:1.30
PE(LYR):4.13
PS:2.00

Loading ...

3SBio Repurchases 1.50 Million Shares for HK$23.59 Million

Bulletin Express
·
Sep 02

3SBIO Uses HK$23.6 Million in Share Buyback on September 2

Stock News
·
Sep 02

3SBio Files HKEX Next-Day Disclosure Return Reporting Share Buyback at HKD 15.72

Reuters
·
Sep 02

CLSA Adjusts 3SBIO Price Target Downward to HK$30.4, Keeps Outperform Rating

Stock News
·
Aug 31

Movement Alert|3SBIO Falls 5.07% in Regular Trading, Pfizer BD Deal Lands with 17% Discount Share Placement Sparking Dilution Concerns

Market Focus
·
Aug 31

CICC Keeps Outperform Rating on 3SBIO, Trims Target Price to HK$30.00

Stock News
·
Aug 24

3SBio (SEHK:1530) Stock Sees Margin Strength Clash With Profit Decline

Simply Wall St.
·
Aug 21

3SBio H1 FY26 Net Profit Rises 26.5% to RMB 1.44 Billion; Revenue Increases 3.9% to RMB 4.53 Billion

Reuters
·
Aug 21

Press Release: 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

Dow Jones
·
Aug 21

Morning Market Pulse: Hang Seng Index Climbs 0.72% in Early Session, Lithium Miners Lead Gains

Stock News
·
Aug 21

Hong Kong Stock Alert: 3SBIO Surges Over 7% on Strong First-Half Adjusted Operating Profit Growth

Stock News
·
Aug 21

Movement Alert|3SBIO Rises 5.58% in Regular Trading, H1 Adjusted Profit Up 26.5% and New Drug Approval Boost Sentiment

Market Focus
·
Aug 21

Press Release: Sunshine Guojian Releases 2026 Interim Report:

Dow Jones
·
Aug 21

China's 3SBio H1 Net Profit Falls on Higher Expenses

Reuters
·
Aug 20

3SBio H1 Revenue RMB 4,526 Million

THOMSON REUTERS
·
Aug 20

China National Medical Products Administration: Approves 3S Guojian's Nonsteroidal Anti-Inflammatory Drug

THOMSON REUTERS
·
Aug 20

Movement Alert|3SBIO Rises 5.15% in Regular Trading, Interim Results Review and Biotech Sector Strength Fuel Gains

Market Focus
·
Aug 20

Earning Preview: 3SBIO Q2 revenue expected to increase, institutional views are mixed-to-cautious

Earnings Agent
·
Aug 13

Movement Alert|3SBIO Rises 5.18% in Regular Trading, Interim Results Review Approaching with Broker Top Pick Catalyst

Market Focus
·
Aug 10

GRAND PHARMA (00512) Secures FDA Fast Track for Its Independently Developed Global First-in-Class RDC Diagnostic for Solid Tumors

Stock News
·
Aug 09